Dr. Zanin-Zhorov is Senior Vice President (SVP) of Translational Medicine at Graviton Bioscience Corporation. Prior to joining Graviton, Dr. Zanin-Zhorov was an SVP of Translational Medicine at Equilibre Biopharmaceutical Corp. (2020-2023), and prior that a Vice President, Head of Immunology at Kadmon Corp. (2012-2020) where she initiated and directed the successful development of a drug candidate, Belumosudil, for chronic Graft Versus Host Disease (cGVHD) which was approved by FDA in 2021. Dr. Zanin-Zhorov oversaw and coordinated many processes during pipeline development from drug design and preclinical testing to selection of clinical indication and biomarker development. Dr. Zanin-Zhorov holds a Ph.D. degree in Immunology from the Weizmann Institute of Science in Israel, and she completed her postdoctoral fellowship at NYU School of Medicine where she led research efforts in defining signaling pathways that control immune cell function in autoimmunity. During her research career Dr. Zanin-Zhorov published more than 30 scientific papers in high-profile journals including Science, PNAS, JCO and she is co-inventor on 13 patents.